trovafloxacin has been researched along with Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marchant, J | 1 |
| Goldstein, EJ | 1 |
1 review(s) available for trovafloxacin and Syndrome
| Article | Year |
|---|---|
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
1 other study(ies) available for trovafloxacin and Syndrome
| Article | Year |
|---|---|
When antibiotics turn toxic.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Antioxidants; Ciprofloxacin; Female; Fluoroquinolones; Genetic Testing; Humans; Inactivation, Metabolic; Levofloxacin; Male; Mice; Mitochondria; Naphthyridines; Ofloxacin; Oxidative Stress; Syndrome; Topoisomerase II Inhibitors; United States; United States Food and Drug Administration | 2018 |